Literature DB >> 7965633

Effects of vif mutations on cell-free infectivity and replication of simian immunodeficiency virus.

I W Park1, K Myrick, J Sodroski.   

Abstract

To investigate the function of the Vif protein of the simian immunodeficiency virus (SIV), mutations were introduced into the SIVmac239 vif gene without affecting the reading frames of other overlapping genes. The phenotypes of these mutant viruses were examined with respect to viral replication and the expression and processing of viral proteins. Transfection of vif-mutant proviral DNA into established T cell lines resulted in a significant delay in the onset of virus replication compared to that seen with the wild-type provirus. The efficiency of replication of the vif-mutant virus was dependent on cell type. MT-4 cells were permissive for replication of the vif mutant, while replication in CEMx174 cells was severely restricted. Little or no virus replication was observed following cell-free infection of the CEMx174 cell line and macaque peripheral blood mononuclear cells (PBMC). These results indicate that the requirement for vif during the replication of SIVmac239 is dependent on cell type, as has been observed for HIV-1. Following cell-free infection, mutant viruses containing combined deletions in vif and the other regulatory genes (vpx, vpr, and nef) displayed replication kinetics similar to that of viruses containing the deletion of vif alone. Viral protein expression and processing in MT-4 cells of vif-deleted viruses were indistinguishable from those of the wild-type virus. The effects of two different point mutations in vif were examined. One point mutant in vif reverted to the genetic sequence of the wild-type virus within 2 weeks.2 +

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965633

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  8 in total

1.  Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription.

Authors:  M Dettenhofer; S Cen; B A Carlson; L Kleiman; X F Yu
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Interaction between Nef and INI1/SMARCB1 augments replicability of HIV-1 in resting human peripheral blood mononuclear cells.

Authors:  Dohun Pyeon; In-Woo Park
Journal:  Arch Virol       Date:  2015-01-07       Impact factor: 2.574

3.  Lentivirus vectors using human and simian immunodeficiency virus elements.

Authors:  S M White; M Renda; N Y Nam; E Klimatcheva; Y Zhu; J Fisk; M Halterman; B J Rimel; H Federoff; S Pandya; J D Rosenblatt; V Planelles
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted.

Authors:  Y Guan; J B Whitney; M Detorio; M A Wainberg
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Atraumatic oral spray immunization with replication-deficient viral vector vaccines.

Authors:  Christiane Stahl-Hennig; Seraphin Kuate; Monika Franz; You S Suh; Heribert Stoiber; Ulrike Sauermann; Klara Tenner-Racz; Stephen Norley; Ki S Park; Young C Sung; Ralph Steinman; Paul Racz; Klaus Uberla
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

6.  Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.

Authors:  Kun Luo; Bindong Liu; Zuoxiang Xiao; Yunkai Yu; Xianghui Yu; Robert Gorelick; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Authors:  Bindong Liu; Xianghui Yu; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.

Authors:  H Liu; X Wu; M Newman; G M Shaw; B H Hahn; J C Kappes
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.